The Journal of Pediatrics
Volume 156, Issue 4 , Pages 537-541 , April 2010

A Follow-up Study of Preterm Infants Given Budesonide Using Surfactant as a Vehicle to Prevent Chronic Lung Disease in Preterm Infants

  • Huang T. Kuo, MD, PhD

      Affiliations

    • Division of Developmental and Behavior Pediatrics, College of Medicine, China Medical University, Taichung, Taiwan
    • Division of Pediatric Neurology, College of Medicine, China Medical University, Taichung, Taiwan
    • ,
  • Hong C. Lin, MD

      Affiliations

    • Division of Neonatology, College of Medicine, China Medical University, Taichung, Taiwan
    • ,
  • Chang H. Tsai, MD, PhD

      Affiliations

    • Division of Pediatric Neurology, College of Medicine, China Medical University, Taichung, Taiwan
    • Department of Biotechnology, Asian University, Wufeng, Taiwan
    • ,
  • I.C. Chouc

      Affiliations

    • Division of Pediatric Neurology, College of Medicine, China Medical University, Taichung, Taiwan
    • ,
  • Tsu F. Yeh, MD, PhD

      Affiliations

    • Division of Neonatology, College of Medicine, China Medical University, Taichung, Taiwan
    • Department of Pediatrics, John H. Stroger Jr Hospital of Cook County, Chicago, IL
    • Corresponding Author InformationReprint requests Dr Tsu F. Yeh, Department of Pediatrics, College of Medicine, China Medical University, 91 Hsieh Shi Road, Taichung, Taiwan.

Received 7 May 2009 ,Revised 11 September 2009 ,Accepted 29 October 2009.

References 

  1. Speer CP. Pre and postnatal inflammation mechanism in chronic lung disease of preterm infants. Pediatr Respir Rev. 2004;5:S241–S244
  2. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics. 1998;101:Available at: www.pediatrics.org/cgi/content/full/101/5/e7
  3. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;1:CD001146
  4. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, et al. Outcome at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004;350:1304–1313
  5. Committee on fetus and newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002;109:330–338
  6. Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight neonates. Cochrane Database Syst Rev. 2003;CD002058
  7. Kovács L, Davis GM, Faucher D, Papageorgiou A. Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. Acta Paediatr. 1998;87:792–798
  8. Cole CH, Colton T, Shah BL, Abbasi S, Mackinnon BL, Demissie S, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med. 1999;340:1005–1010
  9. Yeh TF, Lin HC, Chang CH, Wu TS, Su BH, Li TC, et al. Early Intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics 2008:121:1310–18 or www.pediatrics.org/cgi/content/full/121/5/1310.
  10. Costello de L, Hamilton PA, Baudin J, Townsend J, Bradford B, Stewart AL, et al. Prediction of neurodevelopmental impairment at four years from brain ultrasound appearance of very preterm infants. Dev Med Child Neurol. 1988;30:711–722
  11. Hollingshead AB, Redlich FC. Social stratification and psychiatric disorders. In:  Rose AM editors. Mental Health and Mental Disorders: A Sociological Approach. New York, NY: WW Norton and Co; 1955;
  12. National Asthma Educatia and Prevention Program. Expert Panel Report: guidelines for the diagnosis and management of asthma update on selected topics: 2002. J Allergy Clin Immunol. 2002;110(suppl 5):S141–S219
  13. Brattsand R, Thalen A, Roempke K, Kallstron L, Gruvstad E. Development of new glucocorticosteroids with a very high ratio between topical and systemic activities. Eur J Respir Dis. 1982;122(suppl 2):62–73
  14. Nimmo AJ, Carstairs JR, Patole SK, Whitehall J, Davidson K, Vink R. Intratracheal administration of glucocorticoids using surfactant as a vehicle. Clin Exp Pharmacol Physiol. 2002;29:661–665
  15. Wu TS, Agrawal V, Lin HC, Su BH, Pyati S, Yeh TF. Intratracheal instillation of budesonide (B) by using surfactant (S) as vehicle in VLBW infants at high risk for chronic lung disease: pharmacokinetics and bioavailability of budesonide. E-PAS. 2007;616292.1
  16. Pham S, Wiedmann TS. Note: dissolution of aerosol particles of budesonide in Survanta TM, a model lung surfactant. J Pharmaceutical Sci. 2001;90:98–104
  17. Wiedmann TS, Bhatia R, Wattenberg LW. Drug solubilization in lung surfactant. J Control Release. 2000;65:43–47
  18. Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunke A, Brattsand R. Reversible fatty acid conjugation of budesonide: novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos. 1998;26:623–630
  19. Hvizdos KM, Jarvis B. Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs. 2000;60:1141–1178

 Supported in part by the National Science Council Taiwan (NSC96-2314-B-039-008-MY2). The authors declare no conflicts of interest.

PII: S0022-3476(09)01099-3

doi: 10.1016/j.jpeds.2009.10.049

The Journal of Pediatrics
Volume 156, Issue 4 , Pages 537-541 , April 2010

Article Tools

* Image Usage & Resolution